Company:  JANUX THERAPEUTICS, INC. (JANX)
Form Type:  10-Q
Filing Date:  8/10/2021 
CIK:  0001817713 
Address:  11099 TORREY PINES PARK ROAD 
City, State, Zip:  SAN DIEGO, California 92037 
Telephone:  858-750-4700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$21.51  
Change: 
0.27 (1.27%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$895.06M
Trade JANX now with 

© 2021  
Description of Business
We are an innovative biopharmaceutical company developing next-generation therapeutics based on our proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Our initial focus is on developing a novel class of T cell engagers (TCEs), and our lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors has faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome (CRS), (ii) on-target, healthy tissue toxicities and (iii) poor pharmacokinetics (PK) leading to short half-life. We are using our TRACTr platform technology to engineer product candidates designed to overcome these limitations.
Register and access this filing in:     
  FORM 10-Q
    PART I-FINANCIAL INFORMATION
      Item 1. Financial Statements.
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        CASH FLOW
        Notes to Unaudited Condensed Financial Statements
          BALANCE SHEET
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures.
    PART II-OTHER INFORMATION
      Item 1. Legal Proceedings.
      Item 1A. Risk Factors.
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 3. Defaults Upon Senior Securities.
      Item 4. Mine Safety Disclosures.
      Item 5. Other Information.
      Item 6. Exhibits.
    SIGNATURES
  EXHIBIT 31.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
  EXHIBIT 31.2
    CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO